Biotechnology
Gene editing, cancer biotechnology, regenerative medicine, longevity science and the evidence moving from laboratories into clinical care.
-
Human Brain Tissue Is Growing Inside Mice, Opening a New Window on Disease
Stanford researchers have given human brain tissue more room to develop inside mice. The result is a striking research model—not a human brain or a treatment.
-
A New MRI Dye Could Make Tiny Lung Tumours Harder to Miss
An experimental MRI agent uses the tissue around cancer as a signpost. Mouse results are promising, but human testing still lies ahead.
-
The Next Copper Rush Could Be Powered by Microbes
A new US policy paper puts biomining in the spotlight. Microorganisms already help extract metals, and researchers want to extend that work to more ores and discarded electronics.
-
Prostate Cancer’s DNA Scars Reveal Clues to Its Most Dangerous Behaviour
Researchers have examined 959 prostate tumour genomes to trace the processes damaging their DNA. The findings could help future risk prediction, but they are not a new clinical test.
-
Brain Scans Reveal a Dopamine Clue in Long COVID’s Brain Fog
A small human imaging study has linked long COVID symptoms with changes in a dopamine-related brain marker. It offers a research direction, with important limits on what a scan can prove.
-
Scientists Are Giving Repair Cells an Address for Fragile Bones
A small human trial has tested a striking approach to osteoporosis: changing the sugar coating on a patient’s own cells to help them reach bone marrow. The early signals are promising, but this is still experimental medicine.
-
A Gene Therapy for Childhood Epilepsy Is Aiming Beyond Seizures
ETX101 is producing early signals of fewer seizures and developmental gains in children with Dravet syndrome. Its next challenge is proving those benefits in a controlled trial.
-
A New CAR-T Therapy Takes Aim at Myeloma After Earlier Treatments Fail
Experimental therapy arlo-cel has met key goals in a Phase 2 myeloma trial. Its different cancer-cell target could matter—but the detailed results are still missing.
-
Isembyld Gives SMA Treatment a New Target: Muscle Itself
The FDA has approved the first SMA medicine that directly targets muscle loss. Its trial shows an added motor-function benefit, with important limits and a fracture warning.
-
Scientists Edited Human Embryos. The Safety Warning Is the Real Story.
A new embryo base-editing study pairs a precise DNA result with a warning that should shape the debate about reproductive use.
-
A Daily Eye Drop Could Take the Glare Out of Night Driving
Phase III data suggest that phentolamine eye drops can reduce glare, halos and other dim-light vision problems by gently shrinking the pupil. The treatment remains experimental and is not FDA-approved.
-
A Migraine Pill Is Being Tested for Just Seven Days a Month
A Phase III trial found that taking atogepant around the menstrual period reduced migraine days compared with placebo. The result is promising, but the difference was modest and the short-course regimen is not yet a newly approved use.